These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 3111862)

  • 1. Alternative pathway of complement activation by stimulated T lymphocytes. I. Binding of C3 fragments.
    Sármay G; Ramos OF; Klein E; Kai C; Gergely J
    Eur J Immunol; 1987 Jul; 17(7):969-74. PubMed ID: 3111862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative pathway of complement activation by stimulated T lymphocytes. II. Elevation of cytotoxic potential against complement receptor-carrying cell lines.
    Ramos OF; Sármay G; Eggertsen G; Nilsson B; Klein E; Gergely J
    Eur J Immunol; 1987 Jul; 17(7):975-9. PubMed ID: 3111863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphocytes stimulated by allogeneic B cell lines cleave the third component of complement and fix C3 fragments. Their nonspecific lytic capacity is elevated against complement receptor type 2-carrying targets.
    Ramos OF; Algarra I; Sármay G; Yefenof E; Gergely J; Klein E
    J Immunol; 1989 Jan; 142(1):217-23. PubMed ID: 2521233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments.
    Wåhlin B; Perlmann H; Perlmann P; Schreiber RD; Müller-Eberhard HJ
    J Immunol; 1983 Jun; 130(6):2831-6. PubMed ID: 6222118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Native C3 does not bind to the C3b receptor (CR1) of human blood B lymphocytes or alter immunoglobulin synthesis.
    Berger M; Fleisher TA
    J Immunol; 1983 Mar; 130(3):1021-3. PubMed ID: 6600466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative pathway of complement activation by human lymphoblastoid B and T cell lines.
    Praz F; Lesavre P
    J Immunol; 1983 Sep; 131(3):1396-9. PubMed ID: 6604099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyclonal activation of human lymphocytes in vitro. I. Characterization of the lymphocyte response to a T cell-independent B cell mitogen.
    Schuurman RK; Gelfand EW; Dosch HM
    J Immunol; 1980 Aug; 125(2):820-6. PubMed ID: 6967091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
    Mold C; Nemerow GR; Bradt BM; Cooper NR
    J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of receptors for IgA on mitogen-stimulated human T lymphocytes.
    Millet I; Panaye G; Revillard JP
    Eur J Immunol; 1988 Apr; 18(4):621-6. PubMed ID: 3259188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinctive functional properties of human blood L lymphocytes: a comparison with T lymphocytes, B lymphocytes, and monocytes.
    Horwitz DA; Garrett MA
    J Immunol; 1977 May; 118(5):1712-21. PubMed ID: 140193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The elevated natural killer sensitivity of targets carrying surface-attached C3 fragments require the availability of the iC3b receptor (CR3) on the effectors.
    Ramos OF; Kai C; Yefenof E; Klein E
    J Immunol; 1988 Feb; 140(4):1239-43. PubMed ID: 2963864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative studies of Fc receptors for IgG on resting and activated mouse T lymphocytes using different methods].
    Hückel C; Sandor M; Erdei A; Jensen HL; Brock J; Rychly J; Gergely J
    Allerg Immunol (Leipz); 1986; 32(1):47-56. PubMed ID: 2940850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates.
    Antón LC; Ruiz S; Barrio E; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1994 Mar; 24(3):599-604. PubMed ID: 8125130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B lymphocytes and macrophages release cell membrane deposited C3-fragments on exosomes with T cell response-enhancing capacity.
    Papp K; Végh P; Prechl J; Kerekes K; Kovács J; Csikós G; Bajtay Z; Erdei A
    Mol Immunol; 2008 Apr; 45(8):2343-51. PubMed ID: 18192019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Surface receptors on lymphocytes and blast cells developing from them after a 3-day culture stimulated with concanavalin A].
    Pluzańska A
    Acta Haematol Pol; 1976; 7(3):223-9. PubMed ID: 983670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The third component of complement inhibits human lymphocyte blastogenesis.
    Needleman BW; Weiler JM; Feldbush TL
    J Immunol; 1981 Apr; 126(4):1586-91. PubMed ID: 7204978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine IgA binding factors produced by Fc alpha R(+) T cells: role of Fc gamma R(+) cells for the induction of Fc alpha R and formation of IgA-binding factor in Con A-activated cells.
    Adachi M; Yodoi J; Noro N; Masuda T; Uchino H
    J Immunol; 1984 Jul; 133(1):65-71. PubMed ID: 6233376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surface markers of complement receptor lymphocytes.
    Ross GD; Winchester RJ; Rabellino EM; Hoffman T
    J Clin Invest; 1978 Nov; 62(5):1086-92. PubMed ID: 711854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
    Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
    J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the alternative complement pathway by EBV and the viral envelope glycoprotein, gp350.
    Mold C; Bradt BM; Nemerow GR; Cooper NR
    J Immunol; 1988 Jun; 140(11):3867-74. PubMed ID: 2836501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.